Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 7/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 18/20 | 0.88 |
| ▸ | PTGIR | P43119 | 3/20 | 0.88 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Domitroban SCHEMBL361564 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL3380908 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL7595949 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL9198684 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL13658118 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL9875564 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL2232264 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL2232269 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL2923394 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL7600963 | 0.99 | TBXA2R (0.98) | TBXA2RPTGDRPTGIRTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20180125986-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2018-05-10 | — | — | US | claimed |
| WO-2016102352-A1 | TXA2 INHIBITOR AS STIMULATOR OR INDUCER OF MHC CLASS I CROSS-PRESENTATION | INSTITUT PASTEUR (FR) | 2016-06-30 | — | — | WO | claimed |
| EP-3037106-A1 | TXA2 inhibitor as stimulator or inducer of MHC Class I cross-presentation | INSTITUT PASTEUR (FR) | 2016-06-29 | — | — | EP | claimed |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2015-11-19 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014111957-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | SATYAM APPARAO (IN) | 2014-07-24 | — | — | WO | claimed |
| US-8506935-B2 | Respiratory drug condensation aerosols and methods of making and using them | ALEXZA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20090258075-A1 | Respiratory Drug Condensation Aerosols and Methods of Making and Using Them | ALEXZA PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | claimed |
| CN-101277684-A | Microparticles for the modified release of at least one active principle and oral pharmaceutical forms containing them | FLAMEL TECH SA (FR) | 2008-10-01 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1931320-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | Flamel Technologies (FR) | 2008-06-18 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007036671-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | FLAMEL TECHNOLOGIES (FR) | 2007-04-05 | — | — | WO | claimed |
| US-20040105819-A1 | comprise respiratory drug condensation aerosol particles; selected from the group consisting of beta -adrenergics, methylxanthines, anticholinergics, corticosteroids, mediator-release inhibitors, anti-leukotriene drugs, asthma inhibitors etc | ALEXZA MOLECULAR DELIVERY CORPORATION (US) | 2004-06-03 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20030109543-A1 | Novel combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination | OGLETREE MARTIN L (US) | 2003-06-12 | — | — | US | claimed |
| EP-0906754-B1 | RAPID-RELEASE S1452 TABLETS | SHIONOGI & CO (JP) | 2002-12-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125986-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, NOS3 | TBXA2R 180/4885PTGDR 32/4885PTGIR 8/4885 |
| US-20030109543-A1 | Novel combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination | PTAFR, TBXA2R, PLAT | TBXA2R 2/4885PTGDR 28/4885PTGIR 6/4885 |
| US-20090258075-A1 | Respiratory Drug Condensation Aerosols and Methods of Making and Using Them | LTC4S, PTGER1, PTGES | TBXA2R 47/4885PTGDR 258/4885PTGIR 20/4885 |
| US-20040105819-A1 | comprise respiratory drug condensation aerosol particles; selected from the group consisting of beta -adrenergics, methylxanthines, anticholinergics, corticosteroids, mediator-release inhibitors, anti-leukotriene drugs, asthma inhibitors etc | LTC4S, PTGER1, PTGER4 | TBXA2R 51/4885PTGDR 142/4885PTGIR 29/4885 |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, PTGIS | TBXA2R 181/4885PTGDR 27/4885PTGIR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.